Data supporting the companys lead program currently in Phase 3 testing have been mixed. The company has changed leaders multiple times with Gould stepping down in 2021  returning as CEO in early 2023 and then giving way to new head Alex Sapir in July. And its sickle cell program has been held up since February sending shares to record lows